开云app官网登录入口网页版-官方正版

#注册#

238篇内容 | 2891人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1556930, encodeId=db541556930ed, content=<a href='/topic/show?id=e4016495635' target=_blank style='color:#2F92EE;'>#注册#</a>, objectTitle=小心，注册Meta分析时可能有这些“坑”, objectType=article, longId=730658, objectId=9077e3065826, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9077e3065826, replyNumber=0, likeNumber=80, createdTime=2022-06-29, rootId=0, userName=zhyy93, userId=c52c14833361, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9077e3065826, moduleTitle=小心，注册Meta分析时可能有这些“坑”, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=9077e3065826)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1556929, encodeId=cecc1556929d4, content=<a href='/topic/show?id=e4016495635' target=_blank style='color:#2F92EE;'>#注册#</a>, objectTitle=有偿推广：1分钟注册小程序获20元微信红包, objectType=article, longId=730025, objectId=fb6fe300250f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fb6fe300250f, replyNumber=0, likeNumber=92, createdTime=2022-06-22, rootId=0, userName=zhyy93, userId=c52c14833361, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fb6fe300250f, moduleTitle=有偿推广：1分钟注册小程序获20元微信红包, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=fb6fe300250f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1556928, encodeId=d36a155692811, content=<a href='/topic/show?id=e4016495635' target=_blank style='color:#2F92EE;'>#注册#</a>, objectTitle=Movement Disorders：中国帕金森注册中心来啦：覆盖全国，纳入3000+病人, objectType=article, longId=728964, objectId=74f8e289648f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=74f8e289648f, replyNumber=0, likeNumber=63, createdTime=2022-06-10, rootId=0, userName=zhyy93, userId=c52c14833361, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=74f8e289648f, moduleTitle=Movement Disorders：中国帕金森注册中心来啦：覆盖全国，纳入3000+病人, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=74f8e289648f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1556927, encodeId=b9b0155692e76, content=<a href='/topic/show?id=e4016495635' target=_blank style='color:#2F92EE;'>#注册#</a>, objectTitle=上海推动新冠病毒疫苗注册上市，序贯接种国产mRNA疫苗何时成真？, objectType=article, longId=723495, objectId=6007e23495f7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6007e23495f7, replyNumber=0, likeNumber=72, createdTime=2022-04-06, rootId=0, userName=zhyy93, userId=c52c14833361, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6007e23495f7, moduleTitle=上海推动新冠病毒疫苗注册上市，序贯接种国产mRNA疫苗何时成真？, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=6007e23495f7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1556926, encodeId=9f60155692605, content=<a href='/topic/show?id=e4016495635' target=_blank style='color:#2F92EE;'>#注册#</a>, objectTitle=上海推动新冠病毒疫苗注册上市，序贯接种国产mRNA疫苗何时成真？, objectType=article, longId=302286, objectId=c2863022869b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c2863022869b, replyNumber=0, likeNumber=94, createdTime=2022-04-04, rootId=0, userName=zhyy93, userId=c52c14833361, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c2863022869b, moduleTitle=上海推动新冠病毒疫苗注册上市，序贯接种国产mRNA疫苗何时成真？, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=c2863022869b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1556925, encodeId=b04f155692529, content=<a href='/topic/show?id=e4016495635' target=_blank style='color:#2F92EE;'>#注册#</a>, objectTitle=尘螨变应原舌下片ACARIZAX® 豁免中国注册临床试验，2022年将提交上市许可申请, objectType=article, longId=300863, objectId=f5253008638f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f5253008638f, replyNumber=0, likeNumber=88, createdTime=2022-03-17, rootId=0, userName=zhyy93, userId=c52c14833361, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f5253008638f, moduleTitle=尘螨变应原舌下片ACARIZAX® 豁免中国注册临床试验，2022年将提交上市许可申请, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=f5253008638f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1556924, encodeId=00f615569247a, content=<a href='/topic/show?id=e4016495635' target=_blank style='color:#2F92EE;'>#注册#</a>, objectTitle=AJRCCM：HIV相关肺动脉高压：肺动脉高压协会一项注册登记研究, objectType=article, longId=299237, objectId=08ee29923e39, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=08ee29923e39, replyNumber=0, likeNumber=91, createdTime=2022-02-21, rootId=0, userName=zhyy93, userId=c52c14833361, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=08ee29923e39, moduleTitle=AJRCCM：HIV相关肺动脉高压：肺动脉高压协会一项注册登记研究, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=08ee29923e39)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1556923, encodeId=02d61556923e3, content=<a href='/topic/show?id=e4016495635' target=_blank style='color:#2F92EE;'>#注册#</a>, objectTitle=人工晶状体注册审查指导原则 2022, objectType=article, longId=294651, objectId=39dc294651d6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=39dc294651d6, replyNumber=0, likeNumber=61, createdTime=2022-01-26, rootId=0, userName=zhyy93, userId=c52c14833361, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=39dc294651d6, moduleTitle=人工晶状体注册审查指导原则 2022, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=39dc294651d6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1556922, encodeId=55cf15569223f, content=<a href='/topic/show?id=e4016495635' target=_blank style='color:#2F92EE;'>#注册#</a>, objectTitle=关于公布2021年国家自然科学基金依托单位注册审批结果的通告, objectType=article, longId=293542, objectId=ceb42935427f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ceb42935427f, replyNumber=0, likeNumber=80, createdTime=2022-01-08, rootId=0, userName=zhyy93, userId=c52c14833361, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ceb42935427f, moduleTitle=关于公布2021年国家自然科学基金依托单位注册审批结果的通告, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=ceb42935427f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1556921, encodeId=44111556921d7, content=<a href='/topic/show?id=e4016495635' target=_blank style='color:#2F92EE;'>#注册#</a>, objectTitle=证监会批准同意百济神州科创板IPO注册，拟募资200亿，创历史之最！, objectType=article, longId=220494, objectId=1124220494b7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1124220494b7, replyNumber=0, likeNumber=78, createdTime=2021-11-18, rootId=0, userName=zhyy93, userId=c52c14833361, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1124220494b7, moduleTitle=证监会批准同意百济神州科创板IPO注册，拟募资200亿，创历史之最！, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=1124220494b7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1556920, encodeId=e2b715569203c, content=<a href='/topic/show?id=e4016495635' target=_blank style='color:#2F92EE;'>#注册#</a>, objectTitle=CHEST：美国慢性血栓栓塞性肺动脉高压注册：治疗首选肺动脉内膜切除术!, objectType=article, longId=220065, objectId=f94c220065a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f94c220065a7, replyNumber=0, likeNumber=119, createdTime=2021-11-11, rootId=0, userName=zhyy93, userId=c52c14833361, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f94c220065a7, moduleTitle=CHEST：美国慢性血栓栓塞性肺动脉高压注册：治疗首选肺动脉内膜切除术!, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=f94c220065a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1556919, encodeId=18df1556919a7, content=<a href='/topic/show?id=e4016495635' target=_blank style='color:#2F92EE;'>#注册#</a>, objectTitle=ERJ：肺血管阻力可预测与间质性肺病相关的肺动脉高压患者的死亡率-COMPERA 注册的结果, objectType=article, longId=218499, objectId=caf221849998, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=caf221849998, replyNumber=0, likeNumber=72, createdTime=2021-10-14, rootId=0, userName=zhyy93, userId=c52c14833361, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=caf221849998, moduleTitle=ERJ：肺血管阻力可预测与间质性肺病相关的肺动脉高压患者的死亡率-COMPERA 注册的结果, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=caf221849998)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1556918, encodeId=b50215569186c, content=<a href='/topic/show?id=e4016495635' target=_blank style='color:#2F92EE;'>#注册#</a>, objectTitle=Respirology：澳大利亚和新西兰的慢性血栓栓塞性肺动脉高压:对PHSANZ注册分析, objectType=article, longId=218183, objectId=25592181830a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=25592181830a, replyNumber=0, likeNumber=97, createdTime=2021-10-08, rootId=0, userName=zhyy93, userId=c52c14833361, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=25592181830a, moduleTitle=Respirology：澳大利亚和新西兰的慢性血栓栓塞性肺动脉高压:对PHSANZ注册分析, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=25592181830a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1556917, encodeId=16ab155691e2b, content=<a href='/topic/show?id=e4016495635' target=_blank style='color:#2F92EE;'>#注册#</a>, objectTitle=JNCCN：经肛门直肠全系膜切除术(TaTME) 治疗直肠癌的局部复发和无病生存期:来自国际TaTME注册研究的结果, objectType=article, longId=216818, objectId=d00f21681836, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d00f21681836, replyNumber=0, likeNumber=85, createdTime=2021-09-09, rootId=0, userName=zhyy93, userId=c52c14833361, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d00f21681836, moduleTitle=JNCCN：经肛门直肠全系膜切除术(TaTME) 治疗直肠癌的局部复发和无病生存期:来自国际TaTME注册研究的结果, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=d00f21681836)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1556915, encodeId=7bc3155691560, content=<a href='/topic/show?id=e4016495635' target=_blank style='color:#2F92EE;'>#注册#</a>, objectTitle=The Oncologist：中国胃癌患者不同HER2状态的治疗模式和预后:一项非干预注册研究(EVIDENCE), objectType=article, longId=215442, objectId=6f38215442ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6f38215442ba, replyNumber=0, likeNumber=107, createdTime=2021-08-09, rootId=0, userName=zhyy93, userId=c52c14833361, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6f38215442ba, moduleTitle=The Oncologist：中国胃癌患者不同HER2状态的治疗模式和预后:一项非干预注册研究(EVIDENCE), moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=6f38215442ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1556916, encodeId=790e155691649, content=<a href='/topic/show?id=e4016495635' target=_blank style='color:#2F92EE;'>#注册#</a>, objectTitle=【梅斯小程序】有奖注册：3M听诊器，话费，京东卡，100梅斯积分等你来领, objectType=article, longId=215242, objectId=ee93215242de, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ee93215242de, replyNumber=0, likeNumber=114, createdTime=2021-08-05, rootId=0, userName=zhyy93, userId=c52c14833361, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ee93215242de, moduleTitle=【梅斯小程序】有奖注册：3M听诊器，话费，京东卡，100梅斯积分等你来领, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=ee93215242de)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1556914, encodeId=7dc1155691451, content=<a href='/topic/show?id=e4016495635' target=_blank style='color:#2F92EE;'>#注册#</a>, objectTitle=Lung Cancer：KRAS G12C突变的晚期非小细胞肺癌治疗:来自德国前瞻性、观察性、全国性CRISP注册登记 (AIO-TRK-0315)的真实队列研究, objectType=article, longId=214247, objectId=743821424e04, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=743821424e04, replyNumber=0, likeNumber=73, createdTime=2021-07-16, rootId=0, userName=zhyy93, userId=c52c14833361, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=743821424e04, moduleTitle=Lung Cancer：KRAS G12C突变的晚期非小细胞肺癌治疗:来自德国前瞻性、观察性、全国性CRISP注册登记 (AIO-TRK-0315)的真实队列研究, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=743821424e04)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1556913, encodeId=6a2815569137d, content=<a href='/topic/show?id=e4016495635' target=_blank style='color:#2F92EE;'>#注册#</a>, objectTitle=已经分类注册好的亚群，是否还有必要找差异基因或者进一步分析？, objectType=article, longId=214123, objectId=a4dd21412331, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a4dd21412331, replyNumber=0, likeNumber=84, createdTime=2021-07-14, rootId=0, userName=zhyy93, userId=c52c14833361, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a4dd21412331, moduleTitle=已经分类注册好的亚群，是否还有必要找差异基因或者进一步分析？, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=a4dd21412331)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1556912, encodeId=20811556912d1, content=<a href='/topic/show?id=e4016495635' target=_blank style='color:#2F92EE;'>#注册#</a>, objectTitle=J Clin Med：体重对艾多沙班治疗房颤患者临床结局的影响是什么样的？（ETNA-AF-Europe注册研究）, objectType=article, longId=214020, objectId=4314214020d2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4314214020d2, replyNumber=0, likeNumber=129, createdTime=2021-07-12, rootId=0, userName=zhyy93, userId=c52c14833361, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4314214020d2, moduleTitle=J Clin Med：体重对艾多沙班治疗房颤患者临床结局的影响是什么样的？（ETNA-AF-Europe注册研究）, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=4314214020d2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1556911, encodeId=1ebd1556911ff, content=<a href='/topic/show?id=e4016495635' target=_blank style='color:#2F92EE;'>#注册#</a>, objectTitle=美国医疗补助计划注册人数因新冠疫情激增超8千万, objectType=article, longId=213072, objectId=2e672130e225, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2e672130e225, replyNumber=0, likeNumber=78, createdTime=2021-06-24, rootId=0, userName=zhyy93, userId=c52c14833361, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2e672130e225, moduleTitle=美国医疗补助计划注册人数因新冠疫情激增超8千万, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=2e672130e225)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

注册

2020-05-29

zhyy93 (审核中...)

前往app查看评论内容

#注册#

小心，注册Meta分析时可能有这些“坑”

2022-06-29

zhyy93 (审核中...)

前往app查看评论内容

#注册#

有偿推广：1分钟注册小程序获20元微信红包

2022-06-22

zhyy93 (审核中...)

前往app查看评论内容

#注册#

Movement Disorders：中国帕金森注册中心来啦：覆盖全国，纳入3000+病人

2022-06-10

zhyy93 (审核中...)

前往app查看评论内容

#注册#

上海推动新冠病毒疫苗注册上市，序贯接种国产mRNA疫苗何时成真？

2022-04-06

zhyy93 (审核中...)

前往app查看评论内容

#注册#

上海推动新冠病毒疫苗注册上市，序贯接种国产mRNA疫苗何时成真？

2022-04-04

zhyy93 (审核中...)

前往app查看评论内容

#注册#

尘螨变应原舌下片ACARIZAX® 豁免中国注册临床试验，2022年将提交上市许可申请

2022-03-17

zhyy93 (审核中...)

前往app查看评论内容

#注册#

AJRCCM：HIV相关肺动脉高压：肺动脉高压协会一项注册登记研究

2022-02-21

zhyy93 (审核中...)

前往app查看评论内容

#注册#

人工晶状体注册审查指导原则 2022

2022-01-26

zhyy93 (审核中...)

前往app查看评论内容

#注册#

关于公布2021年国家自然科学基金依托单位注册审批结果的通告

2022-01-08

zhyy93 (审核中...)

前往app查看评论内容

#注册#

证监会批准同意百济神州科创板IPO注册，拟募资200亿，创历史之最！

2021-11-18

zhyy93 (审核中...)

前往app查看评论内容

#注册#

CHEST：美国慢性血栓栓塞性肺动脉高压注册：治疗首选肺动脉内膜切除术!

2021-11-11

zhyy93 (审核中...)

前往app查看评论内容

#注册#

ERJ：肺血管阻力可预测与间质性肺病相关的肺动脉高压患者的死亡率-COMPERA 注册的结果

2021-10-14

zhyy93 (审核中...)

前往app查看评论内容

#注册#

Respirology：澳大利亚和新西兰的慢性血栓栓塞性肺动脉高压:对PHSANZ注册分析

2021-10-08

zhyy93 (审核中...)

前往app查看评论内容

#注册#

JNCCN：经肛门直肠全系膜切除术(TaTME) 治疗直肠癌的局部复发和无病生存期:来自国际TaTME注册研究的结果

2021-09-09

zhyy93 (审核中...)

前往app查看评论内容

#注册#

The Oncologist：中国胃癌患者不同HER2状态的治疗模式和预后:一项非干预注册研究(EVIDENCE)

2021-08-09

zhyy93 (审核中...)

前往app查看评论内容

#注册#

【梅斯小程序】有奖注册：3M听诊器，话费，京东卡，100梅斯积分等你来领

2021-08-05

zhyy93 (审核中...)

前往app查看评论内容

#注册#

Lung Cancer：KRAS G12C突变的晚期非小细胞肺癌治疗:来自德国前瞻性、观察性、全国性CRISP注册登记 (AIO-TRK-0315)的真实队列研究

2021-07-16

zhyy93 (审核中...)

前往app查看评论内容

#注册#

已经分类注册好的亚群，是否还有必要找差异基因或者进一步分析？

2021-07-14

zhyy93 (审核中...)

前往app查看评论内容

#注册#

J Clin Med：体重对艾多沙班治疗房颤患者临床结局的影响是什么样的？（ETNA-AF-Europe注册研究）

2021-07-12

zhyy93 (审核中...)

前往app查看评论内容

#注册#

美国医疗补助计划注册人数因新冠疫情激增超8千万

2021-06-24

科室
- - 订阅+
  - 更多科室
工具
服务